Ezetimibe/simvastatin (Vytorin) vs Rosuvamibe

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Atherosclerotic Cardiovascular Disease

Shared mechanism: HMG-CoA reductase / NPC1L1 · full Atherosclerotic Cardiovascular Disease pipeline

Ezetimibe/simvastatin (Vytorin)

Marketed by Organon

Approved in Atherosclerotic Cardiovascular Diseasesmall molecule combination
Reliable signal

NCT00202878 · Phase 3 · completed

The trial randomly assigned 18,144 participants to Vytorin or simvastatin, used triple blinding, and included an active comparator. Its primary clinical endpoint occurred in 32.72% of the Vytorin group versus 34.67% of the simvastatin group; the difference was statistically significant (hazard ratio 0.936, 95% CI 0.887–0.988; p=0.016).

Reported efficacy

Time to First Occurrence of Cardiovascular Death, Major Coronary Event, or Non-fatal Stroke (Kaplan-Meier Estimate of Percentage of Participants Experiencing a Qualifying Event) (Up to approximately 9 years): Time to First Occurrence of Cardiovascular Death, Major Coronary Event, or Non-fatal Stroke (Kaplan-Meier Estimate of Percentage of Participants Experiencing a Qualifying Event) (Up to approximately 9 years): Ezetimibe/Simvastatin 32.72% (95% CI 31.63 to 33.85) vs Simvastatin 34.67% (95% CI 33.56 to 35.81) (met)

Result source: NCT00202878

Rosuvamibe

Marketed by Yuhan Corporation and partners

small molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Atherosclerotic Cardiovascular Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointEzetimibe/​simvastatin (Vytorin)Rosuvamibe
LDL-C, % change-49.3% vs -38.0%vs Atorvastatin10/20 mg · wk 8 · n 124NCT00496730
3 other results
  • -44.7% vs -27.1% 10/80 mg divided into 4 · wk 6 · n 14 · Phase 4 · primary NCT00762164
  • -53.6% vs -38.3% ezetimibe/simvastatin 10/20mg · wk 6 · Phase 3 · primary NCT00110435
  • -57.6% vs -50.9% ezetimibe/simvastatin 10/40mg · wk 6 · Phase 3 · primary NCT00110435
—Not reported
Non-HDL-C, % change—Not posted · NCT00110435—Not reported
ApoB, % change—Not posted · NCT00110435—Not reported
Lp(a), % change—Not posted · NCT00110435—Not reported
3-point MACE (% with event)—Not posted · NCT00110435—Not reported

LDL-C, % change

Ezetimibe/​simvastatin (Vytorin)
-49.3% vs -38.0%vs Atorvastatin10/20 mg · wk 8 · n 124NCT00496730
3 other results
  • -44.7% vs -27.1% 10/80 mg divided into 4 · wk 6 · n 14 · Phase 4 · primary NCT00762164
  • -53.6% vs -38.3% ezetimibe/simvastatin 10/20mg · wk 6 · Phase 3 · primary NCT00110435
  • -57.6% vs -50.9% ezetimibe/simvastatin 10/40mg · wk 6 · Phase 3 · primary NCT00110435
Rosuvamibe
—Not reported

Non-HDL-C, % change

Ezetimibe/​simvastatin (Vytorin)
—Not posted · NCT00110435
Rosuvamibe
—Not reported

ApoB, % change

Ezetimibe/​simvastatin (Vytorin)
—Not posted · NCT00110435
Rosuvamibe
—Not reported

Lp(a), % change

Ezetimibe/​simvastatin (Vytorin)
—Not posted · NCT00110435
Rosuvamibe
—Not reported

3-point MACE (% with event)

Ezetimibe/​simvastatin (Vytorin)
—Not posted · NCT00110435
Rosuvamibe
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Rosuvamibe: no structured comparison results are available for Atherosclerotic Cardiovascular Disease.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Ezetimibe/simvastatin (Vytorin): 4 of 4 rows · Rosuvamibe: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricEzetimibe/​simvastatin (Vytorin)
Dropout rate
24.3%Ezetimibe/Simvastatina
NCT00202878 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3
show 5 more results
—Ezetimide/Simvastatin
NCT00202878 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3
4.6%10/20 mg
NCT00496730 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3
12.1%10/20 mg
NCT00654628 · Phase 4 · registry result, not featured evidence
17.6%10/80 mg divided into 4
NCT00762164 · Phase 4 · registry result, not featured evidence
14.4%
NCT00442897 · Phase 4 · registry result, not featured evidence
Discontinued due to AEs
—Ezetimibe/Simvastatina
NCT00202878 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3
show 5 more results
—Ezetimide/Simvastatin
NCT00202878 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3
—10/20 mg
NCT00496730 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3
5.2%10/20 mg
NCT00654628 · Phase 4 · registry result, not featured evidence
—10/80 mg divided into 4
NCT00762164 · Phase 4 · registry result, not featured evidence
0.8%
NCT00442897 · Phase 4 · registry result, not featured evidence
Serious AEs
—Ezetimibe/Simvastatina
NCT00202878 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3
show 5 more results
40.1%Ezetimide/Simvastatin
NCT00202878 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3
—10/20 mg
NCT00496730 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3
0.6%10/20 mg
NCT00654628 · Phase 4 · registry result, not featured evidence
0%10/80 mg divided into 4
NCT00762164 · Phase 4 · registry result, not featured evidence
0%
NCT00442897 · Phase 4 · registry result, not featured evidence
Most frequent reported AEs
a
arthralgia 11%
myalgia 10.5%
pain in extremity 10.5%
NCT00202878 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3
show 4 more results
10/20 mg
hypercholesterolaemia 4.8%
hypertriglyceridaemia 3.2%
abdominal pain upper 1.6%
NCT00496730 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3
10/20 mg
myalgia 4%
upper respiratory infection 4%
increased creatine phosphokinase (cpk) 3.5%
NCT00654628 · Phase 4 · registry result, not featured evidence
10/80 mg divided into 4
muscle pain-myalgia 11.8%
NCT00762164 · Phase 4 · registry result, not featured evidence
upper respiratory tract infection 3.7%
headache 1.9%
transaminases increased 1.9%
NCT00442897 · Phase 4 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 3 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Ezetimibe/simvastatin (Vytorin)

CV Death MI or Stroke Composite 32.72% (n=9067) vs 34.67% (n=9077) Simvastatin
responder rate · % of participants
NCT00202878 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3
All-Cause Death MI or Stroke Composite 38.65% (n=9067) vs 40.25% (n=9077) Simvastatin
responder rate · % of participants
NCT00202878 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3
CHD Death/Non-fatal MI or Urgent Revascularization Composite 17.52% (n=9067) vs 18.88% (n=9077) Simvastatin
responder rate · % of participants
NCT00202878 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3
CV Death MI UA Revascularization or Stroke Composite 34.49% (n=9067) vs 36.2% (n=9077) Simvastatin
responder rate · % of participants
NCT00202878 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3
LDL-C -49.29% (n=124) vs -38.05% (n=121) Atorvastatin @ 8wk10/20 mg
percent change · % of baseline
NCT00496730 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3
show 3 more results
-53.6% vs -38.3% atorvastatin 10mg @ 6wkezetimibe/simvastatin 10/20mg
NCT00110435 · Phase 3 · sponsor-reported, not registry data
-44.7% (n=14) vs -27.1% (n=15) Simvastatin @ 6wk10/80 mg divided into 4
NCT00762164 · Phase 4 · registry result, not featured evidence
-57.6% vs -50.9% atorvastatin 40mg @ 6wkezetimibe/simvastatin 10/40mg
NCT00110435 · Phase 3 · sponsor-reported, not registry data
LDL-C Goal Attainment 84.7% (n=124) vs 76.9% (n=121) Atorvastatin @ 8wk10/20 mg
event count · % of participants
NCT00496730 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3 · converted to % from 105 Participants attaining LDL-C goal as posted
LDL-C Goal Attainment 90.4% (n=115) @ 6wk10/20 mg
responder rate · % of participants
No placebo or comparator arm
NCT00654628 · Phase 4 · registry result, not featured evidence
show 1 more result
87.8% (n=49) @ 12wk10/20 mg
NCT00654628 · Phase 4 · registry result, not featured evidence
LDL-C -51.4% (n=152) @ 6wk10/20 mg
percent change · % of baseline
No placebo or comparator arm
NCT00654628 · Phase 4 · registry result, not featured evidence
show 1 more result
-53.8% (n=55) @ 12wk10/20 mg
NCT00654628 · Phase 4 · registry result, not featured evidence
Total Cholesterol -38.1% (n=152) @ 6wk10/20 mg
percent change · % of baseline
No placebo or comparator arm
NCT00654628 · Phase 4 · registry result, not featured evidence
show 1 more result
-39.5% (n=55) @ 12wk10/20 mg
NCT00654628 · Phase 4 · registry result, not featured evidence
HDL-C 4.5% (n=152) @ 6wk10/20 mg
percent change · % of baseline
No placebo or comparator arm
NCT00654628 · Phase 4 · registry result, not featured evidence
show 1 more result
9.4% (n=55) @ 12wk10/20 mg
NCT00654628 · Phase 4 · registry result, not featured evidence
Triglycerides -22.2% (n=152) @ 6wk10/20 mg
percent change · % of baseline
No placebo or comparator arm
NCT00654628 · Phase 4 · registry result, not featured evidence
show 1 more result
-24.7% (n=55) @ 12wk10/20 mg
NCT00654628 · Phase 4 · registry result, not featured evidence
LDL-C -82 mg/dL @ 6wk10/20 mg
absolute change · mg/dL
No placebo or comparator arm
NCT00654628 · Phase 4 · registry result, not featured evidence
show 1 more result
-85.6 mg/dL @ 12wk10/20 mg
NCT00654628 · Phase 4 · registry result, not featured evidence

+ 2 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ezetimibe/simvastatin (Vytorin)'s landscape · Rosuvamibe's landscape